Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.
View / Open Files
Authors
Selby, Nicholas M
Blankestijn, Peter J
Boor, Peter
Combe, Christian
Eckardt, Kai-Uwe
Eikefjord, Eli
Garcia-Fernandez, Nuria
Golay, Xavier
Gordon, Isky
Grenier, Nicolas
Hockings, Paul D
Jensen, Jens D
Joles, Jaap A
Kalra, Philip A
Krämer, Bernhard K
Mark, Patrick B
Mendichovszky, Iosif A
Nikolic, Olivera
Odudu, Aghogho
Ong, Albert CM
Ortiz, Alberto
Pruijm, Menno
Remuzzi, Giuseppe
Rørvik, Jarle
de Seigneux, Sophie
Simms, Roslyn J
Slatinska, Janka
Summers, Paul
Taal, Maarten W
Thoeny, Harriet C
Vallée, Jean-Paul
Wolf, Marcos
Caroli, Anna
Sourbron, Steven
Publication Date
2018-09-01Journal Title
Nephrol Dial Transplant
ISSN
0931-0509
Publisher
Oxford University Press (OUP)
Volume
33
Issue
suppl_2
Pages
ii4-ii14
Language
eng
Type
Article
Physical Medium
Print
Metadata
Show full item recordCitation
Selby, N. M., Blankestijn, P. J., Boor, P., Combe, C., Eckardt, K., Eikefjord, E., Garcia-Fernandez, N., et al. (2018). Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.. Nephrol Dial Transplant, 33 (suppl_2), ii4-ii14. https://doi.org/10.1093/ndt/gfy152
Abstract
Functional renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the management of kidney disease. Such biomarkers are sensitive to changes in renal blood flow, tissue perfusion, oxygenation and microstructure (including inflammation and fibrosis), processes that are important in a range of renal diseases including chronic kidney disease. However, several challenges remain to move these techniques towards clinical adoption, from technical validation through biological and clinical validation, to demonstration of cost-effectiveness and regulatory qualification. To address these challenges, the European Cooperation in Science and Technology Action PARENCHIMA was initiated in early 2017. PARENCHIMA is a multidisciplinary pan-European network with an overarching aim of eliminating the main barriers to the broader evaluation, commercial exploitation and clinical use of renal MRI biomarkers. This position paper lays out PARENCHIMA's vision on key clinical questions that MRI must address to become more widely used in patients with kidney disease, first within research settings and ultimately in clinical practice. We then present a series of practical recommendations to accelerate the study and translation of these techniques.
Keywords
Humans, Disease Progression, Magnetic Resonance Imaging, Renal Insufficiency, Chronic, Biomarkers
Sponsorship
EU COST Action PARENCHIMA
Identifiers
External DOI: https://doi.org/10.1093/ndt/gfy152
This record's URL: https://www.repository.cam.ac.uk/handle/1810/284642
Rights
Attribution-NonCommercial 4.0 International
Licence URL: https://creativecommons.org/licenses/by-nc/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk